Company

Repligen Corporation

Headquarters: Waltham, MA, United States

Founded: 1981

Employees: 1,852

CEO: Mr. Anthony J. Hunt

NASDAQ: RGEN +0.24%

Market Cap

$9.58 Billion

USD as of Jan. 1, 2024

Market Cap History

Repligen Corporation market capitalization over time

Evolution of Repligen Corporation market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Repligen Corporation

Detailed Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Top 1-year algo backtest: +298.72%

$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Repligen Corporation has the following listings and related stock indices.


Stock: NASDAQ: RGEN wb_incandescent

Stock: FSX: RGN wb_incandescent

Product & Services

Materials used in the manufacture of biological drugs

Key People

Founder(s): Alexander Rich Paul Schimmel

Tony J. Hunt (President) and CEO)

Financials

Revenue: US$68 million (2014)

Operating income: US$23 million (2014)


Total assets: US$119 million (2014)

Total equity: US$104 million (2014)

Details

Headquarters:

Building 1

Suite 100 41 Seyon Street

Waltham, MA 02453

United States

Phone: 781 250 0111

Fax: 781 250 0115